BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Watanabe H, Kobayashi A, Hayashi H, Yamazaki N. Effects of long-chain acyl carnitine on membrane fluidity of human erythrocytes. Biochim Biophys Acta. 1989;980:315-318. [PMID: 2540838 DOI: 10.1016/0005-2736(89)90318-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Habartová L, Hrubešová K, Syslová K, Vondroušová J, Fišar Z, Jirák R, Raboch J, Setnička V. Blood-based molecular signature of Alzheimer's disease via spectroscopy and metabolomics. Clin Biochem 2019;72:58-63. [PMID: 30954438 DOI: 10.1016/j.clinbiochem.2019.04.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Siliprandi N, Di Lisa F, Menabó R. Clinical Use of Carnitine Past, Present and Future. In: Grisolía S, Felipo V, Miñana M, editors. Cirrhosis, Hepatic Encephalopathy, and Ammonium Toxicity. Boston: Springer US; 1990. pp. 175-81. [DOI: 10.1007/978-1-4684-5826-8_11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kobayashi A, Watanabe H, Fujisawa S, Yamamoto T, Yamazaki N. Effects of l-carnitine and palmitoylcarnitine on membrane fluidity of human erythrocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1989;986:83-8. [DOI: 10.1016/0005-2736(89)90275-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
4 Soumya R, Vani R. CUPRAC–BCS and antioxidant activity assays as reliable markers of antioxidant capacity in erythrocytes. Hematology 2014;20:165-74. [DOI: 10.1179/1607845414y.0000000177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Arduini A, Gorbunov N, Arrigoni-martelli E, Dottori S, Molajoni F, Russo F, Federici G. Effects of l-carnitine and its acetate and propionate esters on the molecular dynamics of human erythrocyte membrane. Biochimica et Biophysica Acta (BBA) - Biomembranes 1993;1146:229-35. [DOI: 10.1016/0005-2736(93)90360-c] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
6 Bayon JE, Alvarez AI, Barrio JP, Diez C, Prieto JG. Effects of stanozolol and L-carnitine on erythrocyte osmotic fragility during aerobic exercise in rats. Comparative Haematology International 1993;3:196-200. [DOI: 10.1007/bf02341966] [Cited by in Crossref: 4] [Article Influence: 0.1] [Reference Citation Analysis]
7 Wang C, Feng R, Li Y, Zhang Y, Kang Z, Zhang W, Sun D. The metabolomic profiling of serum in rats exposed to arsenic using UPLC/Q-TOF MS. Toxicology Letters 2014;229:474-81. [DOI: 10.1016/j.toxlet.2014.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
8 Nivet J, Le Blanc M, Riess J. Synthesis and preliminary evaluation of perfluoroalkylacyl carnitines as surfactants for biomedical use. European Journal of Medicinal Chemistry 1991;26:953-60. [DOI: 10.1016/0223-5234(91)90138-d] [Cited by in Crossref: 17] [Article Influence: 0.5] [Reference Citation Analysis]
9 Soumya R, Carl H, Vani R. l-carnitine as a Potential Additive in Blood Storage Solutions: A Study on Erythrocytes. Indian J Hematol Blood Transfus 2016;32:328-34. [PMID: 27429526 DOI: 10.1007/s12288-015-0569-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Frezza C, Zheng L, Tennant DA, Papkovsky DB, Hedley BA, Kalna G, Watson DG, Gottlieb E. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011;6:e24411. [PMID: 21912692 DOI: 10.1371/journal.pone.0024411] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
11 Diekman EF, Visser G, Schmitz JP, Nievelstein RA, de Sain-van der Velden M, Wardrop M, Van der Pol WL, Houten SM, van Riel NA, Takken T, Jeneson JA. Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency. PLoS One 2016;11:e0147818. [PMID: 26881790 DOI: 10.1371/journal.pone.0147818] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
12 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
13 Surendran N, Nguyen LD, Giuliano AR, Blanchard J. Enhancement of Calcium Transport in the Caco‐2 Cell Monolayer Model. Journal of Pharmaceutical Sciences 1995;84:410-4. [DOI: 10.1002/jps.2600840406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.0] [Reference Citation Analysis]
14 Arduini A, Rossi M, Mancinelli G, Belfiglio M, Scurti R, Radatti G, Shohet SB. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci 1990;47:2395-400. [PMID: 2263166 DOI: 10.1016/0024-3205(90)90483-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 1.5] [Reference Citation Analysis]
15 Arduini A, Denisova N, Virmani A, Avrova N, Federici G, Arrigoni-Martelli E. Evidence for the involvement of carnitine-dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 1994;62:1530-8. [PMID: 8133280 DOI: 10.1046/j.1471-4159.1994.62041530.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
16 Ravikumar S, Prabhu S, Vani R. Effects of L-carnitine on the erythrocytes of stored human blood. Transfus Med 2020;30:215-25. [PMID: 31701585 DOI: 10.1111/tme.12645] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Goñi FM, Requero MA, Alonso A. Palmitoylcarnitine, a surface-active metabolite. FEBS Lett 1996;390:1-5. [PMID: 8706815 DOI: 10.1016/0014-5793(96)00603-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 1.8] [Reference Citation Analysis]
18 Reuter SE, Faull RJ, Evans AM. L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology (Carlton) 2008;13:3-16. [PMID: 18199095 DOI: 10.1111/j.1440-1797.2007.00817.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
19 Rauchová H, Dobešová Z, Drahota Z, Zicha J, Kuneš J. The effect of chronic l-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. European Journal of Pharmacology 1998;342:235-9. [DOI: 10.1016/s0014-2999(97)01505-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]